JP2025508071A - 純粋な形態の結晶質アチカプラント - Google Patents
純粋な形態の結晶質アチカプラント Download PDFInfo
- Publication number
- JP2025508071A JP2025508071A JP2024553437A JP2024553437A JP2025508071A JP 2025508071 A JP2025508071 A JP 2025508071A JP 2024553437 A JP2024553437 A JP 2024553437A JP 2024553437 A JP2024553437 A JP 2024553437A JP 2025508071 A JP2025508071 A JP 2025508071A
- Authority
- JP
- Japan
- Prior art keywords
- aticaplant
- composition
- crystalline form
- weight
- chemically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317483P | 2022-03-07 | 2022-03-07 | |
| US63/317,483 | 2022-03-07 | ||
| PCT/IB2023/052082 WO2023170547A1 (en) | 2022-03-07 | 2023-03-06 | Pure forms of crystalline aticaprant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025508071A true JP2025508071A (ja) | 2025-03-21 |
| JPWO2023170547A5 JPWO2023170547A5 (https=) | 2026-02-17 |
| JP2025508071A5 JP2025508071A5 (https=) | 2026-02-17 |
Family
ID=85979414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553437A Pending JP2025508071A (ja) | 2022-03-07 | 2023-03-06 | 純粋な形態の結晶質アチカプラント |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230348377A1 (https=) |
| EP (1) | EP4489748A1 (https=) |
| JP (1) | JP2025508071A (https=) |
| KR (1) | KR20240158951A (https=) |
| CN (1) | CN119156210A (https=) |
| AU (1) | AU2023231493A1 (https=) |
| CA (1) | CA3254503A1 (https=) |
| CL (1) | CL2024002643A1 (https=) |
| CO (1) | CO2024012457A2 (https=) |
| IL (1) | IL315411A (https=) |
| JO (1) | JOP20240195A1 (https=) |
| MX (1) | MX2024010978A (https=) |
| PE (1) | PE20242109A1 (https=) |
| TW (1) | TW202345795A (https=) |
| WO (1) | WO2023170547A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5345637B2 (ja) * | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| PH12023552963A1 (en) * | 2021-05-04 | 2024-03-11 | Janssen Pharmaceuticals Inc | Compositions and methods for the treatment of depression |
-
2023
- 2023-03-06 AU AU2023231493A patent/AU2023231493A1/en active Pending
- 2023-03-06 CA CA3254503A patent/CA3254503A1/en active Pending
- 2023-03-06 TW TW112108147A patent/TW202345795A/zh unknown
- 2023-03-06 EP EP23715931.4A patent/EP4489748A1/en active Pending
- 2023-03-06 JP JP2024553437A patent/JP2025508071A/ja active Pending
- 2023-03-06 KR KR1020247033036A patent/KR20240158951A/ko active Pending
- 2023-03-06 US US18/179,025 patent/US20230348377A1/en not_active Abandoned
- 2023-03-06 IL IL315411A patent/IL315411A/en unknown
- 2023-03-06 WO PCT/IB2023/052082 patent/WO2023170547A1/en not_active Ceased
- 2023-03-06 CN CN202380038807.1A patent/CN119156210A/zh active Pending
- 2023-03-06 PE PE2024001920A patent/PE20242109A1/es unknown
-
2024
- 2024-09-03 CL CL2024002643A patent/CL2024002643A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0195A patent/JOP20240195A1/ar unknown
- 2024-09-06 MX MX2024010978A patent/MX2024010978A/es unknown
- 2024-09-13 CO CONC2024/0012457A patent/CO2024012457A2/es unknown
-
2025
- 2025-06-30 US US19/254,965 patent/US20250326714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240158951A (ko) | 2024-11-05 |
| EP4489748A1 (en) | 2025-01-15 |
| JOP20240195A1 (ar) | 2024-09-05 |
| CL2024002643A1 (es) | 2025-01-24 |
| AU2023231493A1 (en) | 2024-10-24 |
| TW202345795A (zh) | 2023-12-01 |
| US20250326714A1 (en) | 2025-10-23 |
| WO2023170547A1 (en) | 2023-09-14 |
| MX2024010978A (es) | 2024-12-06 |
| CN119156210A (zh) | 2024-12-17 |
| CO2024012457A2 (es) | 2024-09-30 |
| PE20242109A1 (es) | 2024-10-28 |
| IL315411A (en) | 2024-11-01 |
| CA3254503A1 (en) | 2023-09-14 |
| US20230348377A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508071A (ja) | 純粋な形態の結晶質アチカプラント | |
| ES2261234T5 (es) | Metabolitos de bupropion y metodos de sintesis y uso. | |
| CA3179785A1 (en) | Advantageous benzofuran compositions for mental disorders or enhancement | |
| JP2025004090A (ja) | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン | |
| EP1988898A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| CN113271936A (zh) | 治疗神经和精神疾病的方法 | |
| CZ20014625A3 (cs) | Vysoce selektivní inhibitory opětovného příjmu norepinefrinu a způsoby jejich pouľití | |
| CN108883110A (zh) | 使用食欲素-2受体拮抗剂治疗抑郁症的方法 | |
| JP2024516297A (ja) | うつ病の治療のための組成物及び方法 | |
| JP2025508069A (ja) | アチカプラントを含む組成物 | |
| US20170096398A1 (en) | Non-hygroscopic salts of 5-ht2c agonists | |
| US20250325515A1 (en) | Forms Of Aticaprant | |
| AU2017321016B2 (en) | Compound for use in the treatment of neurogenic orthostatic hypotension | |
| CZ2003497A3 (cs) | �@Aminoalkylcyklohexanová sloučenina a její použití | |
| CN103635190B (zh) | 治疗方案 | |
| ES2240698T3 (es) | Sales malicas de adicion acida de terbinafina. | |
| CN102516101A (zh) | 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用 | |
| CN121969364A (zh) | 用于在治疗重性抑郁障碍中使用的包含阿替卡普兰的组合物 | |
| HK40057761A (en) | Methods of treating neurological and psychiatric disorders | |
| BR112019003201B1 (pt) | Composto para uso no tratamento de hipotensão ortostática neurogênica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260206 |